OTLK Swing-trade (and potential long-term growth) idea
OTLK (Outlook Therapeutics, Inc.) is expected to commercialize the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan, Greater China and other markets. The stock recently spiked up in anticipation of the most recent earnings report, and experienced a brief pullback as "earnings/news" focused traders took profits. The base appears to have now consolidated, with the down trend now reversing into a positive uptrend with great potential as a swing-trade and long-term investment. (Just my opinion)
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。